 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
16 News |  |
- ||| AlloVax (CRCL/AlloStim) / Immunovative
Trial completion, Phase classification, Enrollment change, Metastases: Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Jan 23, 2020
P2, N=12, Completed, Sponsor: Immunovative Therapies, Ltd.
Active, not recruiting --> Completed | Phase classification: P1/2 --> P2 | N=52 --> 12
- ||| AlloVax (CRCL/AlloStim) / Immunovative
Trial completion, Phase classification, Enrollment change, Trial completion date, Metastases: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - Jan 22, 2020
P2a, N=15, Completed, Sponsor: Immunovative Therapies, Ltd.
Active, not recruiting --> Completed | Phase classification: P1/2 --> P2 | N=52 --> 12 Recruiting --> Completed | Phase classification: P2 --> P2a | N=30 --> 15 | Trial completion date: Aug 2018 --> Mar 2019
- | AlloVax (CRCL/AlloStim) / Immunovative
Enrollment change, Trial withdrawal, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Jan 22, 2020
P2, N=0, Withdrawn, Sponsor: Immunovative Therapies, Ltd.
Recruiting --> Completed | Phase classification: P2 --> P2a | N=30 --> 15 | Trial completion date: Aug 2018 --> Mar 2019 N=100 --> 0 | Not yet recruiting --> Withdrawn
- || AlloVax (CRCL/AlloStim) / Immunovative
Trial primary completion date, Metastases: Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Aug 9, 2016
P1/2, N=52, Active, not recruiting, Sponsor: Immunovative Therapies, Ltd.
N=100 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Jul 2016 --> Dec 2016
- ||| AlloVax (CRCL/AlloStim) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Jul 19, 2016
P2, N=100, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Trial primary completion date: Jul 2016 --> Dec 2016 Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2018 --> Dec 2018
- | AlloVax (CRCL/AlloStim) / Immunovative
Enrollment open, Metastases: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - Jul 13, 2016
P2, N=30, Recruiting, Sponsor: Immunovative Therapies, Ltd.
Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- | AlloVax (CRCL/AlloStim) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - Feb 24, 2016
P2, N=30, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Not yet recruiting --> Recruiting Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Nov 2016 --> Mar 2017
- ||| AlloVax (CRCL/AlloStim) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Feb 24, 2016
P2, N=100, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Nov 2016 --> Mar 2017 Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018
- ||||| AlloVax (CRCL/AlloStim) / Immunovative
New P2 trial, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Dec 10, 2015
P2, N=100, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
- ||| AlloVax (CRCL/AlloStim) / Immunovative
Enrollment closed, Trial primary completion date, Metastases: Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Aug 27, 2015
P1/2, N=52, Active, not recruiting, Sponsor: Immunovative Therapies, Ltd.
Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
- | AlloVax (CRCL/AlloStim) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - Aug 14, 2015
P2, N=30, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jun 2016 --> Oct 2016
- AlloVax (CRCL/AlloStim) / Immunovative
Enrollment change, Trial withdrawal: An Individualized Anti-Cancer Vaccine Study in Patients With HCC (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=0, Withdrawn, Sponsor: Immunovative Therapies, Ltd.
Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jun 2016 --> Oct 2016 N=200 --> 0 | Not yet recruiting --> Withdrawn
- | AlloVax (CRCL/AlloStim) / Immunovative
New P2 trial, Metastases: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - Apr 7, 2015
P2, N=30, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
- |||| AlloVax (CRCL/AlloStim) / Immunovative
Enrollment open, Metastases: Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Feb 20, 2015
P1/2, N=52, Enrolling by invitation, Sponsor: Immunovative Therapies, Ltd.
N=200 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Enrolling by invitation
- ||||| AlloVax (CRCL/AlloStim) / Immunovative
New P1/2 trial, Metastases: Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Nov 27, 2013
P1/2, N=52, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
- ||||| AlloVax (CRCL/AlloStim) / Immunovative
New P1/2 trial: An Individualized Anti-Cancer Vaccine Study in Patients With HCC (clinicaltrials.gov) - Nov 24, 2013
P1/2, N=200, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.